« PhRMA Endorses FDA - NIH Collaboration on Approvals | Main | February - Recipe of the Month - Hearty Tortellini Soup »

02/28/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b01310f47c938970c

Listed below are links to weblogs that reference Diving into Cell Line Platform Development:

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

Bruce Lehr

We frequently use RNAi to validate new targets prior to shifting to ZFNs. RNAi can knock down a gene's expression but won't totally eliminate it and is not permanent. Zinc finger nucleases are very specific enzymatic scissors that can be designed to very specifically remove a single gene (they could also allow you to make a modification in a gene or to insert a gene)and the change is permanent. So as we get into designing platform cell lines for use in production, we go to ZFNs to create a stably modified set of traits. You can read more at this link to Sigma-aldrich site, http://bit.ly/axlyYd

Pharma Conduct Guy

Hi Bruce,

I'm not familiar with the ZFN paradigm. How does it compare to RNAi technologies?

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada